ClinicalTrials.gg
RecruitingNCT07651540NEURONOSCOREUpdated Nov 18, 2026

Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study

An interventional study of Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies. in Sensory Neuronopathy, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 18, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. The functional prognosis of patients with SN is generally poor: in a recent study, two-thirds of patients had a modified Rankin Scale (mRS) score ≥3 and nearly half had an mRS ≥4.

The absence of reliable biomarkers in neuropathies justifies the use of clinical scales as indicators of disease severity, disability, and treatment response. However, none of the currently available "general neuropathy" scales have been specifically designed or validated for SN. The only scale developed specifically for SN is the SEARS (Sensory Ataxia Rating Scale), proposed in 2019, but it has not been widely used nor validated in large populations.

As a result, the absence of a clinical scale specifically designed for patients with SN makes longitudinal follow-up more challenging, particularly when assessing the response to immunomodulatory or immunosuppressive treatments when these therapies are indicated.

02

Conditions studied

  • Sensory Neuronopathy

Keywords

  • neurology
  • specific scale
  • rare neuropathy
03

In context

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient affiliated with or beneficiary of a social security system
  • Patient having received appropriate study information
  • Adult patient ≥18 years old, male or female
  • Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria
  • SN with one of the following etiologies:

Paraneoplastic SN with anti-Hu or anti-CV2/CRMP5 antibodies SN associated with Sjögren's syndrome, systemic lupus erythematosus, or primary biliary cholangitis Platinum-salt-induced SN SN caused by CANVAS syndrome

Exclusion criteria

Exclusion Criteria:

  • Patient unable to understand or read French
  • Patient refusal to participate
  • Patient known to have another neuropathy phenotype and/or etiology that could significantly influence clinical scales and electrophysiological parameters, including:

    • Diabetes mellitus
    • Significant alcohol consumption
    • Severe chronic kidney disease ( \<30 ml/min)
    • Vitamin B12 and/or vitamin E deficiency
    • Vitamin B6 excess
    • Chemotherapy other than platinum salts
    • infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Group experimental

    Other: Longitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies.

Interventions

  • OtherLongitudinal monitoring of clinical assessment scores to identify the most appropriate tool for tracking disease progression in sensory neuronopathies.

    After patient consent, three follow-up visits (T0, T6, T12) will be scheduled. Some information will already be collected at baseline (demographics, medical history, comorbidities). Three visits will be conducted: (T0), Follow-up at 6 months (T6), Follow-up at 12 months (T12) At each visit the following will be assessed: Clinical scales: mISS, SEARS, CADT, SARA, ONLS, I-RODS, 9-Hole Peg Test, Timed Up and Go test, mRS, Quantified Rydel tuning fork test, Visual Analog Scale (VAS) ENMG including sensory nerve action potentials of the radial and sural nerves (antidromic recording

06

What researchers measure

Primary outcomes

  1. The Clinical Global Impression of Change (CGI-C) and The Patient Global Impression of Change (PGI-C).

    Global Impression of change measure evaluating overall change in clinical status compared with baseline.

    Time frame: 6 months and 12 months

Secondary outcomes

  1. miSS Score change

    Change in mISS score from baseline.

    Time frame: 6 months and 12 months

  2. SEARS change

    Change in SEARS score from baseline.

    Time frame: 6 months, 12 months

  3. CADT change

    Change in CADT score from baseline.

    Time frame: 6 months and 12 months

  4. SARA change

    Change in SARA score from baseline.

    Time frame: 6 months and 12 months

  5. ONLS change

    Change in ONLS score from baseline.

    Time frame: 6 months and 12 months

  6. I-RODS change

    Change in I-RODS score from baseline.

    Time frame: 6 months and 12 months

  7. 9-Hole Peg Test change

    Change in 9-Hole Peg Test score from baseline.

    Time frame: 6 months and 12 months

  8. Timed Up and Go test change

    Change in Timed Up and Go test from baseline

    Time frame: 6 months and 12 months

  9. Modified Rankin Scale change

    Change in Modified Rankin Scale from baseline

    Time frame: 6 months and 12 months

  10. Quantified Rydel tuning fork test change

    Change in Quantified Rydel tuning fork test from baseline

    Time frame: 6 months and 12 months

  11. Visual Analog Scale change

    Change in Visual Analog scale frome baseline

    Time frame: 6 months and 12 months

  12. Electroneuromyography

    Change in Electroneuromyography from baseline

    Time frame: 6 months and 12 months

07

Study locations

3 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jun 2028, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 16, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Jun 25, 2028
CompletionEst.
Jun 25, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Chu de Clermont Ferrand · Clermont-Ferrand, FranceNot yet recruiting→Recruiting
  • CHU St Etienne · Saint-Etienne, FranceNot yet recruiting→Recruiting
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Chu de Clermont Ferrand · Clermont-Ferrand, FranceNot yet recruiting→Recruiting
    • CHU St Etienne · Saint-Etienne, FranceNot yet recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07651540
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Jul 6, 2026
Primary completion
Jun 25, 2028 (estimated)
Completion
Jun 25, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Jean philippe PHD CAMDESSANCHE
Contact
j.philippe.camdessanche@chu-st-etienne.fr
+33 4 77 12 05 59
Clara PFENNINGER
Contact
clara.pfenninger@chu-st-etienne.fr
+33 4 77 12 02 87

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion